ExpreS2 Platform Licensed by Boston Children’s Hospital
News Oct 10, 2015
ExpreS2ion Biotechnologies has announced the execution with Boston Children’s Hospital ("Boston Children’s”), located in Boston, Massachusetts, USA, of a non-exclusive research license agreement to use ExpreS2ion’s proprietary recombinant protein expression platform ExpreS2 for Boston Children’s academic research. Boston Children’s is the pediatric teaching affiliate of Harvard Medical School.
The ExpreS2 platform is being used by top academic and top private industry teams to solve protein expression challenges. The system has proven to be instrumental in advancing research in neglected diseases, including malaria research and vaccine projects, where other expression systems have failed to yield the native properties of the parasite proteins – or even failed to express the proteins. ExpreS2 provides high quality, very homogenous expressed proteins, qualities that are needed in structural biology studies.
“ExpreS2ion aims to support the development of novel drugs through solving protein production challenges. Our proprietary technology platform can deliver protein for laboratory use and is also compatible with current Good Manufacturing Practice (cGMP). This interaction with Boston Children’s is part of our strategy to support top academic teams in protein expression. It is our hope that this license will advance the understanding of relevant immunological processes and of malaria vaccine candidates.” said Wian de Jongh, Ph. D., Chief Scientific Officer, ExpreS2ion.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE